Is Apogee Therapeutics Inc. (APGE) Stock Outpacing Its Medical Peers This Year?
Here is how Apogee Therapeutics Inc. (APGE) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.
APGE - Apogee Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$122.75
DETAILS
HIGH:
$140.00
LOW:
$81.00
MEDIAN:
$135.00
CONSENSUS:
$122.75
DOWNSIDE:
8.51%
Stock News
3 Reasons to Buy AbbVie Stock Like There's No Tomorrow
It looks like a great buy-and-hold option.
Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals
Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon lose patent protection.
Are AVB, LPRO, APGE, TMHC Obtaining Fair Deals for their Shareholders?
Are AVB, LPRO, APGE, TMHC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 6, 2026
Are AVB, LPRO, APGE, TMHC Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for Public Shareholders
MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apogee (NASDAQ: APGE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with CRH. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.
Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for Public Shareholders
MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apogee (NASDAQ: APGE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with CRH.
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?
AbbVie knows how to plan ahead.
Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026
Biotech ETF Index Surges 10% After Rebalance
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.
Is AbbVie a Buy After Its Purchase of Apogee?
The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propo
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apogee Therapeutics, Inc. (NasdaqGM: APGE) to AbbVie (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Apogee will receive $135.11 in cash for each share of Apogee that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequa.
Here Are Wednesday’s Best Wall Street Analyst Research Calls: Devon Energy, Flowserve, Klaviyo, Macerich, Merck, Nucor, Take-Two Interactive Software, Twilio, and More
Pre-Market Stock Futures: Futures are trading higher this morning, but if you've ever heard the old saying, "when the chips are down", that was the poster child phrase for Tuesday's session, as technology stocks, and specifically the semiconductor stocks, followed a worldwide sell-off that initially began in Korea and carried around the globe. When... Here Are Wednesday's Best Wall Street Analyst Research Calls: Devon Energy, Flowserve, Klaviyo, Macerich, Merck, Nucor, Take-Two Interactive Software, Twilio, and More
Nova Minerals redomiciles to US as Alaska gold and antimony work accelerates
Nova Minerals Corp (ASX:NVA, NYSE-A:NVA, FRA:QM30) has completed its redomicile to the United States and started key 2026 field work at its Estelle Gold and...
G50 Corp strikes high-grade gold at first White Caps core hole in Nevada
G50 Corp Ltd (ASX:G50, OTCQB:GFYTF) has delivered a strong first result from its 2026 core drilling program at the White Caps Gold Project in Nevada,...
Empire Metals to host investor presentation on Pitfield progress
Empire Metals Ltd (AIM:EEE, OTCQX:EPMLF), the AIM-quoted and OTCQX-traded exploration and development company, will present to investors on 30 June....
Metals One builds 5.57% stake in newly listed Talon Resources
Metals One PLC (AIM:MET1, FRA:HT7, OTCQB:MTOPF), the gold and uranium developer and investor, has built a 5.57% stake in Talon Resources. The holding was...
Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer
On June 22, 2026, Apogee Therapeutics shares surged as investors reacted to AbbVie's proposed acquisition terms.
Price Targets
Apogee Therapeutics downgraded to Hold from Buy at Stifel
$135.00
(was $132.97)
Stifel Nicolaus
Mizuho Downgrades Apogee Therapeutics Inc (APGE) to Neutral
$135.00
(was $132.88)
Joseph Catanzaro
·
Mizuho Securities
Apogee Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
$135.00
(was $132.55)
RBC Capital
Apogee Therapeutics downgraded to Neutral from Buy at UBS
$135.11
(was $132.55)
UBS
Apogee Therapeutics downgraded to Hold from Buy at Deutsche Bank
$135.00
(was $132.55)
David Hoang
·
Deutsche Bank
Apogee Therapeutics downgraded to Hold from Buy at Craig-Hallum
$135.11
(was $132.65)
Craig-Hallum
Apogee Therapeutics Inc (APGE) PT Raised to $97 at RBC Capital
$97.00
(was $86.92)
Brian Abrahams
·
RBC Capital
Apogee Therapeutics moved to Neutral at Goldman Sachs
$89.00
(was $77.50)
Goldman Sachs
Apogee Therapeutics price target lowered to $81 from $83 at Truist
$81.00
(was $78.07)
Danielle Brill
·
Truist Financial
Apogee Therapeutics price target raised to $135 from $120 at Wedbush
$135.00
(was $81.72)
Wedbush
Apogee Therapeutics initiated with a Buy at Rothschild & Co Redburn
$140.00
(was $82.89)
Qize Ding
·
Redburn Partners
Truist Securities Starts Apogee Therapeutics Inc (APGE) at Hold
$83.00
(was $69.85)
Danielle Brill
·
Truist Financial
Apogee Therapeutics Inc (APGE) PT Lowered to $95 at Jefferies
$95.00
(was $65.99)
Akash Tewari
·
Jefferies
Apogee Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
$83.00
(was $81.91)
RBC Capital
Apogee Therapeutics price target raised to $116 from $109 at Craig-Hallum
$116.00
(was $78.20)
Craig-Hallum
Apogee Therapeutics price target raised to $137 from $128 at BTIG
$137.00
(was $76.78)
BTIG
Apogee Therapeutics price target raised to $133 from $95 at Stifel
$133.00
(was $76.34)
Stifel Nicolaus
Apogee Therapeutics initiated with an Overweight at Stephens
$95.00
(was $74.78)
Stephens
Apogee Therapeutics initiated with a Buy at Deutsche Bank
$103.00
(was $74.75)
Deutsche Bank
Apogee Therapeutics initiated with a Buy at Craig-Hallum
$109.00
(was $56.63)
Craig-Hallum